Biotech6 hours ago
AbbVie and Simcere Zaiming Partner on Trispecific Antibody for Multiple Myeloma in $1.055B Deal
AbbVie and Simcere Zaiming announced a licensing option agreement to develop SIM0500, a trispecific antibody targeting multiple myeloma. Currently in Phase I trials, SIM0500 induces strong...